Dialog Abstract File 155 Accesion No. 92257868, Kaklamanis, 1992. Clin Rheumatol. 11(1):41-47. |
Reclini et al. 1988. (Abstract: Dialog File 155 Accession No. 88326267) Biochem. J. 252(2):515-519. |
Murav'ev, 1980. (Abstract: Biosis No.: 73034154) Ter Arkh 52(11):126-129. |
Marra et al. Aug. 23, 1990. (Abstract; WPI Accession No.: 90-274947/36. |
Azizkhan et al., "Mast Cell Heparin Stimulates Migration of Capillary Endothelial Cells In Vitro," J. Exp. Med., 152:931-944 (Oct. 1980). |
Brahn, "Animal Modles of Rheumatoid Arthritis," Clin. Orthopaedics and Related Res., 265:42-53 (Apr. 1991). |
Castellot et al., "Heparin Potentiation of 3T3-Adipocyte Stimulated Angiogenesis: Mechanism of Action on Endothelial Cells," J. Cell. Phys.127:328-329 (1986). |
Cremer et al., "Collagen-Induced Arthritis In Rats," J. Immunol., 149(3):1045-1053 (Aug. 1, 1992). |
Folkman et al., "Angiogenesis Inhibition and Tumor Regression Caused by Heparin or a Heparin Fragment in the Presence of Cortisone," Science, 221:719-725 (Aug. 19, 1983). |
Gallagher, "Heparan Sulphates as Membrane Receptors for the Fibroblast Growth Factors," Eur. J. Clin. Chem. Clin. Biochem., 32(4):239-247 (1994). |
Harris, "Rheumatoid Arthritis Pathology and Implications for Therapy," New Engl. J. Med., 322(18):1277-1289 (1990). |
Ishihara et al., "A Cell Based Assay for Evaluating the Interaction of Heparin-like Molecules and Basic Fibroblast," Analytical Biochem., 202:310-315 (1992). |
Kingsley and Sieper, "Current perspectives in reactive arthritis," Immunol. Today, 14(8):387-391 (1993). |
Leff, "NCI Seeks Company To Co-Develop Anti-Cancer Drugs That Block Tumor Angiogenesis," BioWorld Today, 7(125):1&5 (Jun. 26, 1996). |
Lichtman et al., "Reactivation of Arthritis Induced by Small Bowel Bacterial Overgrowth in Rats: Role of Cytokines, Bacteria, and Bacterial Polymers," Infect. Immun., 63(6):2295-2301 (Jun. 1995). |
Mitchell and Wilks, "Inhibitors of Angiogenesis", Chapter 15, pp. 139-148 in Annual Reports in Medical Chemistry, vol. 27, Academic Press, Inc. (1992). |
Murav'ev et al., "Effect of Heparin Therapy on Clinico-Laboratory Indicators In Rheumatoid Arthritis Patients," Ter. Arkh., 52(11);126-129 (1980)--English translation. |
Phadke et al., "Evaluation of the Effects of Various Anti-Arthritic Drugs on Type II Collagen-Induced Mouse Arthritis Model," Immunopharmacology, 10:51-60 (1985). |
Stuart et al., "Nature and the Specificity of the Immune Response to Collagen in Type II Collagen-induced Arthritis in Mice", J. Clin. Invest., 69:673-683 (Mar. 1982). |
Vogel et al., "Modulation of Endothelial Cell Proliferation, Adhesion, and Motility by Recombinant Heparin-Binding Domain and Synthetic Peptides From the Type I Repeats of Thrombospondin", J. Cellular Biochem., 53:74-84 (1993). |
Weiss et al., "Determinants of the Action of Phospholipases A on the Envelope Phospholipids of Escherichia coli," J. Biol. Chem., 254(21):11010-11014 (1979). |
Wooley, "Animal models of rheumatoid arthritis," Curr. Opp. Rheumat., 3:407-420 (1991). |
Yayon et al., "Cell Surface, Heparin-Like Molecules are Required for Binding of Basic Fibroblast Growth Factor to Its High Affinity Receptor", Cell, 64:841-848 (Feb. 22, 1991). |
Charles, et al., J. Biol. Chem., "The Three-dimensional Structure of Bovine Platelet Factor 4 at 3.0 A Resolution," 264(4):29092-2099 (Feb. 5, 1989). |
Cook, et al., Circulation, "Platelet Factor 4 Efficiently Reverses Heparin Anticoagulation in the Rat Without Adverse Effects of Heparin-Protamine Complexes," 85(3): 1102-1109 (Mar., 1992). |
Elsbach, et al., Inflammation: Basic Principles and Correlates, "Oxygen-Independent Antimicrobial Systems of Phagocytes," 2nd. Ed., Review Press, Ltd. Chapter 30, pp. 603-636 (1992). |
Elsbach, et al., J. Biol. Chem., "Separation and Purification of a Potent Bactericidal/Permeability-increasing Protein and a closely Associated Phospholipase A.sub.2 from Rabbit Polymorphonuclear Leukocytes," 254(21): 11000-11009 (Nov. 10, 1979). |
Folkman, et al., Inflammation: Basic Principles and Correlates, "Abiogenesis and Inflammation," 2nd, Ed., Review Press, Ltd., Chapter 40, pp. 821-839 (1992). |
Gammon, et al., J. Exp. Med., "T Cell Determinant Structure: Cores and Determinant Envelopes in Three Major Mouse Hsitocompatability Complex Halotypes," 173:609-617 (Mar., 1991). |
Garcia, et al., BioWorld Today, "Repligen IND for Platelet Factor," p. 5 (Jan. 11, 1983). |
Gazzano-Santoro, et al., Infect. Immunol., "High Affinity Binding of the Bactericidal/Permeability Increasing Protein and a Recombinant Amino-Terminal Fragment to the Lipid A Region of Lipopolysacchride," 60(11): 4754-4761 (Nov., 1992). |
Gray, et al., J. Biol. Chem., "Cloning of the cDNA of a Human Neutrophil Bactericidal Protein," 264(16): 9505-9509 (Jun. 5, 1989). |
Heyderman, et al., Thrombosis Res., "Reduction of the Anticoagulant Activity of Glycosaminoglycans on the Surface of the Vascular Endothelium by Endotoxin and Neutrophils: Evaluation by an Amidolytic Assay," 67: 677-685 (Apr. 28, 1992). |
Hiti-Harper, et al., Science, "Platelet Factor 4: An Inhibitor of Collagenase," 199: 991-992 (Mar. 3, 1978). |
Maeji, et al. J. Immunol. Methods, "Multi-pin Peptide Strategy for T cell determinant analysis," 134: 23-33 (1990). |
Maione, et al., Cancer Res., "Inhibition of Tumor Growth in Mice by an Analogue of Platelet Factor 4 That Lacks Affinity for Heparin and Retains Potent Angiostatic Activity," 51:2077-2083 (Apr. 15, 1991). |
Maione, et al., CAS BioTech Updates--Antibody Conjugates, pp. 1, 1334, 117:226303x (Issue Jun. 16, 1992). |
Marra, et al., J. Immunol., "The Role of Bactericidal/Permeability-Increasing Protein as a Natural Inhibitor of Bacterial Endotoxin," 148:532-537 (Jan. 15, 1992). |
Weiss, et al., J. Clin. Invest., "Partial Characterization and Purification of a Rabbit Granulocyte Factor That Increases Permeability of Escheria coli," 55:33-42 (1975). |
Yayon, et al., Cell, "Cell Surface, Heparin-like Molecules Are Required for Binding of Basic Fibroplast Growth to its High Affinity Recptor," 64:641-648 (Feb. 22, 1991). |
Yong, et al., Microbial Pathogenesis, "An experimental mouse model of Yersinia-induced reactive arthritis," 4:305-310 (1988). |
Merrifield, et al., Anal. Chem., "Instrument for Automated Synthesis of Peptides," 38(13): 1905-1914 (Dec., 1966). |
Merrifield, et al., J. Am. Chem. Soc., "Solid Phase Peptide Synthesis," 85: 2149-2154 (Jul. 20, 1963). |
Miles, et al., VII International Conference on Aids, Florence, Italy, "Recombinant Platelet Factor 4 (rPF4) and a Non-heparin Binding Derivative Inhibit Aids-Kaposi Sarcoma Derived Cell Lines," Paper 41(8), W.A. 1066 p. 108 (Jun. 16-21, 1991). |
Ooi, et al., J. Exp. Med., "Endotoxin-neutralizing Properties of the 25kD N-Terminal Fragment and a New Isolated 30 kD C-Terminal Fragment of the 55-60 kD Bactericidal/Permability-increasing Protein of Human Neutrophils," 174: 649 (1991). |
Peacock, et al., J. Exp. Med., "Angiobiogenesis Inhibition Suppresses Collagen Arthritis," 175: 1135-1138 (Apr., 1992). |
Repligen Corporation, Research in Review, Spring 1992. |
Stuart, et al., J. Clin. Invest., "Nature and the Specificity of the Immune Response to Collagen in Type II Collagen-induced Arthritis in Mice," 69: 673-683 (Mar., 1982). |
Takayama, et al., Infect. and Immun., "Absence of Lipopoylsaccharide in the Lyme Disease Spirochete," 55(9): 2311-2312 (Sep., 1987). |
Taylor, et al., Nature, "Protamine is an inhibitor of angiogenesis," 297:307-312 (May 27, 1982). |
Tontsch, et al., Microvascular Res., "Isolation, Characterization, and Long-Term Cultivation of Porcine and Murine Cerebral Capillary Endothelial Cells," 37:148-161 (1981). |
Weiss, et al., Blood, "Cellular and Subcellular Localization of the Bactericidal/Permeability-Increasing Protein of Neutrophils," 69(2): 652-659 (Feb., 1987). |